The FDA has approved MSD’s Welireg for rare adrenal tumours, and AbbVie’s Emrelis for treating c-Met+ lung cancer patients.

The US Food and Drug Administration (FDA) has accepted BioCryst Pharmaceuticals’ new drug application (NDA) for Orladeyo.

As pressure to comply with stringent environmental regulations mounts, could green chemistry strategies provide the solution?

Pharmaceutical Technology Excellence Awards are now open for submissions, and you can download our Research Guide for more ...

From predictive analytics to robotic warehousing, automation is unlocking new efficiencies in pharma logistics.

The French drugmaker said it would commit at least $20bn in the US through 2030, with the aim to increase R&D and ...

AbbVie has signed a collaboration and licensing agreement with US-based ADARx Pharmaceuticals, committing $335m upfront to ...

Kaerus Bioscience has received US Food and Drug Administration’s (FDA) designations for KER-0193 to treat Fragile X syndrome ...

Boehringer Ingelheim has entered a multi-year partnership with Tempus AI to progress its cancer treatment pipeline.

A new specialist manufacturing facility in Scotland could soon provide solutions to scaling challenges for vital ...

Recipharm has joined forces with ProductLife Group (PLG) to support (bio)pharmaceutical firms in expediting market approval ...

This follows what appeared to be a generally positive data readout for belrestotug at ESMO 2024 just a few months ago.